TRIUMPH-4 Phase 3 in Obesity Plus Knee Osteoarthritis: 28.7% Weight Loss and 75.8% Pain Reduction at 68 Weeks
ADA 2026 brought full TRIUMPH-4 results in adults with obesity and knee osteoarthritis. At the 12 mg dose, mean weight loss reached 28.7% at 68 weeks, and WOMAC pain scores dropped by an average of 4.5 points, a 75.8% reduction. The combination of substantial weight loss with a directly measured pain-and-function benefit positions retatrutide as the first obesity drug to land both endpoints in a single Phase 3.